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ABSTRACT
Graft-versus-host (GVH) disease (GVHD) continues to be a major life-threatening complication after alloge-
neic bone marrow transplantation. Considerable progress has been made elucidating the pathophysiology of
acute GVHD. Mature donor T cells transferred along with the marrow graft directly recognize antigenic
differences on antigen-presenting cells of the host. Once activated, donor antihost-specific T cells can mediate
tissue destruction. Interestingly, the failure to clonally delete autoreactive T cells in the thymus can also lead
to an autoimmune syndrome mimicking the pathology of GVHD. Negative selection in the thymus may be
compromised either by damage to the thymic epithelium (because of a direct attack by donor antihost
alloreactive T cells) or by the use of immunosuppressive drugs that inhibit clonal deletion. An important
component underlying GVHD mediated by either alloreactive or autoreactive T cells is the absence of a
competent peripheral regulatory system. Studies in animal model systems clearly indicate that regulatory T
cells play a vital role in down-regulating GVHD and are critically important for the establishment of active
dominant tolerance to both allo- and self-major histocompatibility complex antigens. Although multiple
populations of cells appear to participate in this process, CD4 regulatory T cells that innately express CD25
appear to orchestrate the regulatory control of the immune response. Evidence for regulatory T cells in clinical
bone marrow transplantation, however, remains rudimentary. The recent identification that CD4CD25
regulatory T cells preferentially express the Foxp3 nuclear transcription factor and the development of
molecular reagents to isolate antigen-specific T cells have provided unique opportunities to explore immu-
noregulatory mechanisms after clinical marrow transplantation. Recent studies in recipients of clinical bone
marrow transplantation suggest that antigen-specific CD4CD25Foxp3 T cells play a vital role in the
regulatory control of GVH reactions mediated by both alloreactive and autoreactive lymphocytes. These
regulatory T cells also appear to facilitate the establishment of donor antihost and donor antidonor (self)
tolerance.
© 2006 American Society for Blood and Marrow Transplantation
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dGraft-versus-host (GVH) disease (GVHD) is a
ajor life-threatening complication of allogeneic
one marrow transplantation (BMT). Although a ma-
or cause of morbidity and mortality, GVHD does
ppear to have an antitumor effect [1-4]. Patients who
esolve their GVHD have much lower rates of tumor
ecurrence compared with patients who do not de-
elop this posttransplantation complication. Despite
upported by grants CA15396 and CA82853 from the National Insti-
hutes of Health.
B&MThe development of superior postgrafting immunosup-
ressive regimens, GVHD continues to be a signiﬁ-
ant clinical problem particularly for patients receiv-
ng bone marrow grafts from unrelated donors [5].
During the past decade, considerable progress has
een made elucidating the pathophysiology of acute
VHD. After allogeneic BMT, a GVH reaction is
nitiated when mature donor T cells transferred along
ith the marrow graft directly recognize antigenic
ifferences on antigen-presenting cells (APCs) of the
ost [6-9]. Activated donor antihost-speciﬁc T cells
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1xpand in the developing “cytokine storm” and medi-
te tissue destruction that is normally conﬁned to the
kin, liver, and gastrointestinal tract as schematically
llustrated in Figure 1. Although GVHD was classi-
ally thought to be caused by histocompatibility dif-
erences between donor and host as postulated by
illingham[10] in the late 1960s, studies during the
ast several years reveal that GVHD can also occur in
atients receiving autologous bone marrow grafts or
one marrow grafts from identical twins [11-14]. The
athology of this autoimmune or autologous GVHD
as primarily limited to the skin with pathology vir-
ually identical to the GVHD that occurs after allo-
eneic BMT. One of the principle mechanisms
hought to underlie autologous GVHD is a failure of
lonal deletion mechanisms in the thymus [11-15].
lonal deletion of autoreactive T cells is thought to be
he central mechanism in preventing the development
f autoaggression. Damage to the thymic epithelium
y the BMT preparative regimen may also compro-
ise the ability of the thymus to negatively select or
elete the autoreactive T cells [16]. Autoreactive T
ells capable of recognizing self-major histocompati-
ility complex (MHC) class II antigens are thought to
ediate this autoimmune GVHD [15]. Recent studies
uggest that autoimmunity may also emerge during
cute GVHD after allogeneic BMT. Damage to the
hymic epithelium by antihost reactive T cells impairs
egative selection in the thymus subsequently leading
o the export of autoreactive T lymphocytes into the
eriphery [17,18]. These autoreactive T cells appear
o be broadly speciﬁc, capable of recognizing both self
donor) and host MHC class II antigens. Thus, auto-
eactive T cells broadly speciﬁc for MHC class II
eterminants may participate in acute allogeneic
VHD and are thought to underlie the pathophysi-
logy of chronic GVHD with its clinical autoimmune
igure 1. Schematic illustration of effector mechanism involved in
ith bone marrow graft recognize and respond to histocompatibili
elease of autoreactive T cells that may participate in GVH re
hymic-dependent clonal deletion inducing release of autoreactive
VHD.anifestations [17-20]. p
4The importance of the thymus in autoimmune
VHD was further elucidated in studies with cyclo-
porine (CsA), an immunosuppressive drug that di-
ectly inhibits thymic-dependent clonal deletion [21].
dministration of CsA after autologous or syngeneic
MT, in fact, facilitates the induction of autologous
VHD [15,22-24]. Animal studies revealed that the
resence of a thymus was a critical requirement for the
nduction of autologous GVHD because this autoim-
une disorder could not be induced if the recipients
f autologous/syngeneic BMT underwent thymec-
omy before transplantation [25]. Interestingly, stud-
es evaluating the immunobiologic mechanisms asso-
iated with CsA-induced autologous GVHD revealed
hat the effector T cells were also broadly speciﬁc,
ecognizing both allo- and self-MHC class II anti-
ens presenting class II invariant chain peptide
CLIP) [26-29]. The invariant chain shepherds the
iosynthesis of MHC class II. As the MHC class II
olecule is transported to the cell surface, the invari-
nt chain is proteolyzed, leaving CLIP in the peptide-
inding domain. Interestingly, the broad or promis-
uous speciﬁcity of the effector T cells appeared to be
overned by a functional and agonistic interaction
etween the N-terminal ﬂanking domain of CLIP and
he V chain of the T-cell receptor at or near the
inding site for the superantigen, staphylococcal en-
erotoxin B as illustrated in Figure 2. Interestingly,
utoreactive effector T cells with identical speciﬁcity
MHC class II-CLIP) were detected in patients with
utologous BMT who developed autologous GVHD
fter administration of CsA [29]. Clonal analysis of the
utoreactive effector mechanisms in the animal model
f autologous GVHD revealed functionally distinct
ubsets of MHC class II to CLIP reactive autoreactive
cells that differentially require either the N- or the
-terminal ﬂanking domain of CLIP [26-31]. The
eic and autologous GVHD. Alloreactive T cells transferred along
en differences in host. Damage to thymic epithelium may induce
Administration of CsA to autologous BMT recipients inhibits
ls that can manifest autoaggression that is identical to allogeneicallogen
ty antig
sponse.
T celathogenic autoreactive T cells that mediate the pa-
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Regulatory T Cells and GVHD
Bhology of this autoimmune disorder preferentially
equired the N-terminal ﬂanking domain of CLIP
hereas the C-terminal ﬂanking domain–dependent
ubset of autoreactive lymphocytes included regula-
ory T cells (see below) [30,31].
An important component underlying both alloge-
eic and autologous GVHD is the absence of a pe-
ipheral regulatory system capable of down-regulating
he pathogenic potential of the alloreactive and auto-
eactive effector T cells, respectively [32-34]. In allo-
eneic GVHD, the regulatory component must be
enerated to ameliorate the pathogenic effects of the
lloreactive effector T cells. Comparatively, the reg-
latory mechanism controlling the development of
utologous GVHD is present in healthy animals but
liminated by the preparative regimen used for BMT.
his regulatory system is a peripheral safeguard to
ontrol the activity of T cells with autoreactive poten-
ial that were not centrally deleted in the thymus. The
limination of this T cell–dependent regulatory sys-
em, in fact, provides a permissive environment for the
lloreactive and autoreactive effector T lymphocytes
o manifest tissue destruction. The resolution of both
llogeneic and autologous GVHD is dependent on the
econstitution and establishment of a peripheral reg-
latory system. Once the regulatory T-cell system is
ctivated, the activity of the pathogenic effector lym-
hocytes can be effectively down-regulated. More-
ver, donor-to-host and self-tolerance is established.
igure 2. Recognition of MHC class II to CLIP complex in autol-
gous GVHD. Autologous effector T cells recognize MHC class II
ntigens presenting CLIP. In addition to recognition of MHC class
I binding domain of CLIP, N-terminal ﬂanking domain appears to
nteract with V chain of T-cell receptor at or near binding site for
taphylococcal enterotoxin B superantigen.Observations both in human beings and in animals d
B&MTlearly indicated that a number of individuals who
evelop acute GVHD after allogeneic BMT eventu-
lly recover. Studies in animal models suggested that
he down-regulation of acute allogeneic GVHD and
he establishment of donor-to-host tolerance was me-
iated by antigen-speciﬁc regulatory T cells [34-41].
nitial characterization of this peripheral regulatory
ystem suggested that both CD8 and CD4 T cells
ere required for the establishment of donor-to-host
olerance. Further studies suggested that the CD8
egulatory T cells do not express the CD28 costimu-
atory cell-surface accessory molecule [42]. The im-
une tolerance that developed in the recipient of
llogeneic BMT was antigen-speciﬁc and could be
doptively transferred into naive hosts [34-37]. Of
nterest, donor-to-host tolerance mediated by regula-
ory T cells failed to develop in thymectomized ani-
als [34-37]. These results suggested that the thymus
as critically important for the de novo development
f regulatory T cells after allogeneic BMT. Moreover,
aintenance of donor-to-host tolerance by donor an-
ihost-speciﬁc regulatory T cells was dependent on
he continued presence of host MHC antigens, par-
icularly MHC class II antigens [36]. In the absence of
peciﬁc antigen, regulatory T-cell activity waned rap-
dly. Although distinct subsets of T cells play an im-
ortant role in peripheral regulation of the immune
esponse, recent studies suggest that CD4 T cells that
nnately express CD25 (interleukin [IL}-2 receptor
-chain) orchestrate the regulation of GVHD and the
evelopment of donor-to-host tolerance [34,43,44].
his population of regulatory lymphocytes may work
irectly or in concert with CD8 CD28- T cells that
ave regulatory function to effectively down-regulate
he immune response. The CD4 CD25 regulatory
opulation arises naturally in the thymus and is posi-
ively selected by dendritic cells. Moreover, MHC
lass II expression was critical for the development of
D4 CD25 T cells with regulatory potential
44,45]. Of interest, recent studies indicate that Has-
all’s corpuscles in the thymus instruct dendritic cells
o positively select the regulatory T-cell population
46]. Development of functional activity within the
D4 CD25 regulatory compartment and the abil-
ty to control responses to alloantigens appears to
equire an antigenic signal [41,47-49]. Interestingly, a
ubset of CD4CD25- T cells, once activated, may
lso acquire regulatory function. After activation, the
egulatory T cells capable of modulating GVHD are
nduced to express high levels of L-selectin [50].
oreover, recent studies suggest that subsets of APCs
rovide speciﬁc signals allowing for the activation and
aturation of regulatory T cells [51].
Regulatory mechanisms also play a critical role in
reventing the development of autologous GVHD as
evealed in animal models of this autoaggression syn-
rome [15,23,33]. Mature T cells from naive animals
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1ere able to suppress both the induction and the
doptive transfer of autologous GVHD. In this set-
ing, effective suppression of autologous GVHD re-
uired both CD4 and CD8 T cells. Moreover, the
esolution of autologous GVHD and the re-establish-
ent of self-tolerance were critically dependent on the
econstitution of the peripheral immunoregulatory
ystem [52,53]. In addition, recent studies suggest that
his regulatory system is adaptive [30,33,52,53]. The
resence of autoreactive lymphocytes or the autoan-
igen presented on APCs induces dynamic changes in
he functional behavior of the peripheral regulatory
ystem including the activation (or expansion) of an-
igen-speciﬁc CD4 CD25 regulatory T cells.
rimed by the presence of autoreactive T cells or the
ntigen, the regulatory T cells are now capable of
uppressing the adoptive transfer of autologous
VHD independent of CD8 T cells [33]. Of inter-
st, recent studies indicate that both the antigen-spe-
iﬁc regulatory and pathogenic effector T cells in
utologous GVHD recognize a common peptide an-
igen framework presented by MHC class II mole-
ules [28,31]. These two subsets of MHC class II to
LIP autoreactive T cells are differentially dependent
n the N- and C-terminal ﬂanking domains of the
LIP. Although the pathogenic T cells are restricted
y the N-terminal domain, a subset of lymphocytes
hat preferentially require the C-terminal ﬂanking do-
ain of CLIP reside within CD4 CD25 regulatory
-cell compartment [28,31]. Interestingly, a truncated
ariant of CLIP that only contains the MHC class II
nd C-terminal ﬂanking domains when presented on
PCs speciﬁcally activate this regulatory population
53]. Taken together, an activation signal conveyed
ither by the autoreactive T cells (perhaps mediated
y the cell-surface expression of the MHC class II-
LIP complex on activated T cells) or by speciﬁc
ntigen presented on APCs appears to be required for
he development of functional regulatory activity. It is
mportant to note that in activated T cells in the rat
odel the regulatory T cells may directly recognize
igure 3. Development of donor-to-host and self-tolerance. Re
lloreactive and autoreactive T cells. CD4CD25Foxp3 T cells
D8CD28- regulatory T cells may also interact to facilitate this state of
6his antigenic complex on the activated effector lym-
hocytes [28,33]. On the other hand, the apparent
nitial requirement for CD8 T regulatory cells from
aive animals and their functional role in suppressing
he adoptive transfer of autologous GVHD remain
nclear. Perhaps CD4 CD25 regulatory T cells
nce activated can interact with and direct CD8
egulatory T cells newly formed that arise through
ormal T-cell differentiation in the thymus within the
ost. Nevertheless, the CD4 CD25 regulatory T-
ell subset plays a crucial role in preventing autoag-
ression and promoting the development of immune
olerance to self-MHC class II antigens after autolo-
ous BMT.
The regulatory control of a GVH response medi-
ted either by alloreactive or autoreactive T cells is
omplex. Although multiple populations of cells ap-
ear to participate in this process, recent preclinical
tudies suggest that naturally occurring CD4 CD25
egulatory T cells are vital for the regulation of the
mmune response to both allo- and self-MHC anti-
ens as illustrated in Figure 3 [43,47-49]. Moreover,
his population of regulatory T cells must be recon-
tituted after allogeneic or autologous BMT. Interest-
ngly, the regulatory compartments controlling both
lloreactivity and autoreactivity are, in fact, remark-
bly parallel, perhaps differing only in the antigen
peciﬁcity of the regulatory cells. The underlying mo-
ecular mechanisms accounting for regulation of the
mmune response, however, remain controversial. A
umber of mechanisms have been proposed including
he release of regulatory cytokines (i.e., IL-10, trans-
orming growth factor ) that can dampen the im-
une response, the induction of unresponsiveness to
ntigen (T-cell anergy) or induce the apoptotic death
f the pathogenic autoreactive effector T cells [43,47-
9]. The general consensus is that cell-to-cell contact is
equired for effective regulation of the immune re-
ponse. One of the limiting factors that hinders the
n-depth characterization of the CD4 CD25 regu-
atory T-cell compartment is the lack of suitable
tion of regulatory compartment allows for down-regulation of
ed by APCs may orchestrate establishment of immune tolerance.constitu
activatunresponsiveness.
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Regulatory T Cells and GVHD
Barkers unique to regulatory lymphocytes. Because
ctivated CD4 and CD8 effector T cells can also
xpress CD25, this marker is not unique to regulatory
cells. Recent studies, however, suggest that the
orkhead-winged helix family, nuclear transcription
actor Foxp3 is speciﬁcally expressed by naturally oc-
urring CD4 CD25 regulatory T cells [54,55].
oxp3 appears to be a “master gene” governing the
evelopment and suppressive function of CD4
D25 regulatory T cells [55]. Animals deﬁcient in
oxp3 develop widespread autoimmune disorders as a
esult of the lack of regulatory T cells [54-56]. A
umber of studies in animal systems clearly conﬁrm
hat CD4 CD25 Foxp3 T cells participate in the
egulatory control of allogeneic and autologous
VHD [57]. In addition, CD8 CD28- regulatory T
ells may also express Foxp3[58].
Evidence for the regulatory control of GVHD and
he development of tolerance (donor to host, self) in
linical BMT is quite limited. Functional assays to
etect regulatory activity in recipients of clinical BMT
ere often hindered because patients and donors were
atched for MHC class I and II antigens. In this
etting, an assay to assess the regulation of donor
ntihost reactivity (i.e. by culture of donor and host
ymphocytes harvested pretransplantation) by regula-
ory T cells was absent. In addition, cells that sup-
ressed in an antigen nonspeciﬁc manner were often
etected in the BMT recipient. The role of these
onspeciﬁc regulatory cells remains ill deﬁned. Apart
rom these rudimentary functional assays, the lack of
peciﬁc markers for regulatory T cells also precluded
he quantitative analysis of cell-mediated immune reg-
latory mechanisms after clinical BMT. The ﬁndings
hat naturally occurring CD4 regulatory T cells in-
ately express the CD25 cell-surface molecule and the
oxp3 nuclear transcription factor has provided a
nique opportunity to quantify and correlate regu-
atory T-cell function in human BMT recipients.
everal studies indicate that naturally occurring
D4CD25 T cells that can suppress in vitro im-
une responses can be detected in human peripheral
lood [46-49]. Moreover, the Foxp3 nuclear transcrip-
ion factor appears to be preferentially expressed by
he CD4 CD25 regulatory T-cell compartment.
nterestingly, CD4 CD25 regulatory T cells also
nnately express high levels of cytotoxic lymphocyte-
ssociated antigen 4, the regulatory cell-surface acces-
ory molecule [46-49,57]. Comparatively, expression
f other markers including programmed death recep-
or 1 and glucocorticoid-induced tumor necrosis fac-
or receptor could not effectively distinguish among
D4CD25 T cells from CD4CD25-, activated
D4CD25 effector, and CD8 effector T lympho-
ytes [57]. Thus, the results from these studies clearly
uggest that Foxp3 might be a useful marker to assess h
B&MTnd quantify CD4 CD25 regulatory T cells in clin-
cal BMT recipients.
Recent studies by Miura et al. [57] in a series of
atients undergoing allogeneic or autologous BMT
ith the experimental induction of autologous GVHD
rovide substantial evidence that CD4 CD25
oxp3 T cells play a central role in regulating both
lloimmune and autoimmune reactivity. Flow cyto-
etric assessment of Foxp3 expression is difﬁcult be-
ause it is an intracellular nuclear transcription factor.
oxp3 gene expression in this study was quantiﬁed by
valuating messenger RNA (mRNA) transcript levels
or this nuclear transcription factor as assessed by
uantitative polymerase chain reaction. Analysis of
eripheral blood lymphocytes revealed that Foxp3
RNA transcript levels were signiﬁcantly reduced in
atients with either allogeneic or autologous GVHD
ompared with patients who did not develop any clin-
cal evidence of GVHD (either allogeneic or autolo-
ous) (Figure 4). Of particular interest are the results
rom patients with acute allogeneic GVHD demon-
trating that expression of Foxp3 was inversely corre-
ated with the grade of acute allogeneic GVHD as
emonstrated in Figure 5. Levels of Foxp3 mRNA
ranscripts in peripheral blood lymphocytes were al-
ost undetectable in patients with grade III or grade
V acute GVHD. Foxp3 mRNA transcript levels were
lso signiﬁcantly reduced (2-fold) in patients with
rade I or II acute allogeneic GVHD compared with
atients who did not develop any evidence of this
osttransplantation complication after allogeneic BMT.
nalysis of a limited number of patients with chronic
llogeneic GVHD indicated that Foxp3 levels were
lso signiﬁcantly reduced, particularly for patients
ho had extensive disease. Interestingly, sequential
nalysis of the lymphocytes from a patient with acute
igure 4. Decreased Foxp3 gene expression in patients with
VHD. Peripheral blood lymphocytes were collected and assessed
or levels of Foxp3 mRNA transcripts by quantitative polymerase
hain reaction [57]. Data were standardized against the glyceralde-
yde phosphate dehydrogenase housekeeping gene.
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1VHD that evolved into a chronic GVHD revealed
hat levels of Foxp3 mRNA transcripts were consis-
ently reduced while the patient had active disease
Figure 6A). After resolution of GVHD, levels of
oxp3 mRNA transcripts returned to normal. The
eturn to normal levels of Foxp3 gene expression also
orrelated with de novo T-cell development as re-
ealed by the assessment of T-cell recombination ex-
ision circles. These results suggest that the regulatory
cells that mediate the down-regulation of GVHD
re recent thymic emigrants. The emergence of this
egulatory population, in fact, coincides with the res-
lution of GVHD.
Recent studies by Zorn et al. [59] conﬁrm and
xtend the ﬁndings in patients with chronic allogeneic
igure 5. Correlation of Foxp3 gene expression with grade of acu
evels of Foxp3 mRNA transcripts by quantitative polymerase chain
ehydrogenase housekeeping gene. Expression levels of Foxp3 wer
igure 6. Temporal analysis of Foxp3 expression in patients devel-
ping allogeneic and autologous GVHD. Foxp3 mRNA transcripts
ere assessed in peripheral blood lymphocytes collected sequentially
rom patient with allogeneic GVHD (A) or patient with autologous
VHD (B) as previously described [57]. Levels of mRNA transcriptseere correlated with disease stage.
8VHD. Foxp3 gene expression was signiﬁcantly re-
uced in patients who develop chronic GVHD after
llogeneic BMT. Phenotypic studies also revealed that
here was a reduced frequency of CD4 CD25 T
ells in patients with chronic GVHD. Of interest, the
egulatory T cells derived from patients with chronic
VHD were capable of suppressing in vitro immune
eactivity. Strategies to expand this population may
rovide a novel therapeutic approach to control or
revent the development of allogeneic GVHD.
As indicated above, the results in patients with
utologous GVHD induced by administering CsA af-
er autologous BMT were remarkably similar with
evels of Foxp3 mRNA transcripts signiﬁcantly re-
uced in patients who develop autologous GVHD. In
ddition, patients followed up sequentially after autol-
gous BMT with the induction of autologous GVHD
lso revealed that Foxp3 expression level was minimal
uring active GVHD, but returned to normal levels
oinciding with the resolution of this autoaggression
yndrome (Figure 6B). Identiﬁcation of the major tar-
et antigen as the MHC class II to CLIP complex in
utologous GVHD has provided a unique opportunity
o further evaluate immunoregulatory mechanisms in
linical BMT recipients. Recent studies in the animal
odel of autologous GVHD suggest that antigen-
peciﬁc effector and regulatory T cells can be isolated
sing a soluble immunoglobulin, MHC class II con-
truct loaded with CLIP [27,29]. Similar studies were
onducted in patients with autologous BMT (treated
ith CsA to induce autologous GVHD) using a solu-
le tetrameric MHC class II (DR2) molecule loaded
ith CLIP. CD4 MHC class II to CLIP reactive T
ells were isolated by 2-color ﬂow cytometry from
atients pretransplantation, during active autologous
VHD, and after resolution of this autoaggression
yndrome (Figure 7A). The CD4 MHC class II to
LIP reactive T cells were assessed for levels of Foxp3
RNA transcripts. Foxp3 gene expression was mark-
D. Peripheral blood lymphocytes were collected and assessed for
on [57]. Data were standardized against glyceraldehyde phosphate
lated with grade of acute GVHD and stage of chronic GVHD.te GVH
reactidly reduced in the CD4 MHC class II to CLIP
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Regulatory T Cells and GVHD
Beactive T-cell subset isolated during active autolo-
ous GVHD compared with cells isolated pretrans-
lantation. Interestingly, expression of Foxp3 was
learly heightened in CD4 MHC class II to CLIP
eactive T cells isolated within 2 weeks after resolu-
ion of autologous GVHD (Figure 7B). The enhanced
xpression was independent of number of T cells. It
ppears that there was a compensatory ampliﬁcation
f regulatory cells (expressing Foxp3) that modify the
ctivity of the autologous GVHD effector cells. In
ddition, these results also imply that the regulatory
ells involved in the regulation of this autoaggression
yndrome may also be speciﬁc for the target antigen of
igure 7. Analysis of CLIP reactive CD4 T cells after autologous B
sed to isolate CD4 T cells that recognized MHC class II to CLIP
sothiocyanate conjugated CD4 and phycoerythrin conjugated DR2
rom patient pretransplantation, during active autologous GVHD
ranscript levels by quantitative polymerase chain reaction.
igure 8. In vitro stimulation of regulatory T-cell function. Periph
resented by autologous APCs as previously described [57]. Varian
-terminal ﬂanking domain (N-CLIP), and BD with C-terminal do
fter stimulation (A). Cells were harvested and assessed for their
timulated with autologous APCs that innately express MHC class II to CLI
B&MThe autologous GVHD effector T lymphocytes. Inter-
stingly, studies in the animal model of autologous
VHD reveal that both the antigen-speciﬁc regula-
ory and pathogenic effector T cells in autologous
VHD recognize a common peptide antigen frame-
ork presented in the context of MHC class II.
Additional studies by Miura et al. [57] assessed
hether regulatory T-cell function could be height-
ned by antigen-speciﬁc stimulation. Studies in the
reclinical animal model of autologous GVHD sug-
ested that the effector and regulatory T cells have
ifferential requirements for the N- and C-terminal
anking domains of CLIP. Based on these ﬁndings, a
nd induction of autologous GVHD. Two-color ﬂow cytometry was
ex (A). Peripheral blood lymphocytes were stained with ﬂuoroscein
mer loaded with CLIP. CD4CLIP reactive T cells were isolated
pon resolution of autoaggression and assessed for Foxp3 mRNA
ood lymphocytes were stimulated with truncated variants of CLIP
LIP included MHC class II binding domain (BD), BD along with
LIP-C). Levels of Foxp3 mRNA transcripts were assessed 24 hours
to suppress proliferative response of autologous CD8 T cellsMT a
compl
a tetra
and ueral bl
ts of C
main (C
abilityP complex. Proliferation was assessed after 72 hours of culture [57].
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2eries of studies were undertaken assessing whether
eptide variants of CLIP with each of the ﬂanking
omains selectively deleted and presented by autolo-
ous APCs could stimulate the CD4 regulatory T-
ell compartment. Stimulation of CD4 T cells with
he CLIP variant containing the C-terminal ﬂanking
omain not only induced the up-regulation of Foxp3
xpression but also heightened their regulatory func-
ion as summarized in Figure 8. These results further
upport the concept that regulatory T cells involved in
ontrolling the development and resolution of autol-
gous GVHD may be speciﬁc for the same target
eptide antigen as the autoreactive effector T cells.
he apparent selectivity or restriction to the peptide
ith the C-terminal ﬂanking domain of CLIP of the
egulatory T cells remains unknown. Recent studies
uggest that this peptide variant may modify APC
unction [60]. Nevertheless, these results suggest that
egulatory T-cell function can be heightened by anti-
en stimulation, an approach that may have therapeu-
ic implications.
Although many questions remain, studies in a va-
iety of animal models have clearly deﬁned the impor-
ance of regulatory T cells in controlling alloreactivity
nd autoreactivity. Evidence for regulatory T cells in
linical settings remains rudimentary. The recent
dentiﬁcation of CD4 T cells that innately express
D25 and the Foxp3 nuclear transcription factor and
he development of molecular reagents to isolate an-
igen-speciﬁc T cells, however, have provided unique
pportunities to explore immunoregulation in human
eings. More importantly, strategies to expand this
opulation by ex vivo culture or in vivo by speciﬁc
timulation (i.e., antigen/APCs, infusion of apoptotic
ells) will help to devise novel therapeutic strategies to
ontrol untoward immune responses.
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